Prodrugs of thrombin inhibitors

Details Prodrugs of thrombin inhibitors Prodrugs of thrombin inhibitors

2008-04-08

2008-04-08

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S019300, C514S210030, C530S331000, C530S380000, C424S009100, C435S214000, C548S953000, C560S035000, C560S168000

Reexamination Certificate

active

10776245

ABSTRACT:
There is provided compounds of formula I,in-line-formulae description="In-line Formulae" end="lead"?R1O(O)C—CH2—(R)Cgl-Aze-Pab-R2Iin-line-formulae description="In-line Formulae" end="tail"?wherein R1and R2have meanings given in the description, which are useful as prodrugs of inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (eg thrombosis) or as anticoagulants.

REFERENCES:
patent: 4346078 (1982-08-01), Bajusz et al.
patent: 4568636 (1986-02-01), Svendsen
patent: 4703036 (1987-10-01), Bajusz et al.
patent: 4977168 (1990-12-01), Bernat et al.
patent: 5037819 (1991-08-01), Han
patent: 5110812 (1992-05-01), Han
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5260307 (1993-11-01), Ackermann et al.
patent: 5273982 (1993-12-01), Alig et al.
patent: 5561146 (1996-10-01), Kim et al.
patent: 5583146 (1996-12-01), Kimball et al.
patent: 5602253 (1997-02-01), Antonsson et al.
patent: 5614499 (1997-03-01), Bylund et al.
patent: 5629324 (1997-05-01), Vacca et al.
patent: 5705487 (1998-01-01), Schacht et al.
patent: 5707966 (1998-01-01), Schacht et al.
patent: 5710130 (1998-01-01), Schacht et al.
patent: 5726159 (1998-03-01), Schacht et al.
patent: 5744487 (1998-04-01), Ohshima et al.
patent: 5786383 (1998-07-01), Clement
patent: 5965692 (1999-10-01), Gustafsson et al.
patent: 6262028 (2001-07-01), Antonsson et al.
patent: 0 074 787 (1983-03-01), None
patent: 0 192 135 (1986-03-01), None
patent: 0 185 390 (1986-06-01), None
patent: 0 195 212 (1986-09-01), None
patent: 0 235 692 (1987-09-01), None
patent: 0 293 881 (1988-12-01), None
patent: 0 362 002 (1990-04-01), None
patent: 0 364 344 (1990-04-01), None
patent: 0 364 344 (1990-04-01), None
patent: 0 468 231 (1991-01-01), None
patent: 0 479 489 (1991-09-01), None
patent: 0 468 231 (1992-01-01), None
patent: 0 471 651 (1992-02-01), None
patent: 0 513 543 (1992-11-01), None
patent: 0 526 877 (1993-02-01), None
patent: 0 526 877 (1993-02-01), None
patent: 0 530 167 (1993-03-01), None
patent: 0 542 525 (1993-05-01), None
patent: 0 559 046 (1993-09-01), None
patent: 0 601 459 (1994-06-01), None
patent: 0 641 779 (1995-03-01), None
patent: 0 648 780 (1995-04-01), None
patent: 0 669 317 (1995-08-01), None
patent: 0 686 642 (1995-12-01), None
patent: 2 085 444 (1982-04-01), None
patent: WO 9 204 371 (1992-03-01), None
patent: WO 9 208 709 (1992-03-01), None
patent: WO 9 207 869 (1992-05-01), None
patent: WO 93/11152 (1993-06-01), None
patent: WO 93/18060 (1993-09-01), None
patent: WO 94/29336 (1994-12-01), None
patent: WO 95/01168 (1995-01-01), None
patent: WO 95/23609 (1995-09-01), None
patent: WO 95/35309 (1995-12-01), None
patent: WO 96/14084 (1996-05-01), None
patent: WO 96/16671 (1996-06-01), None
patent: WO 96/25426 (1996-08-01), None
patent: WO 96/31504 (1996-10-01), None
patent: WO 96/32110 (1996-10-01), None
Boykin et al, “Anti-Pneumocystis Activity of Bis-Amidoximes and Bis-O-Alkylamidoximes Prodrugs”, Bioorganic & Medicinal Chemistry Letters 6(24):3017-3020 (1996).
Taylor, “Improved passive oral drug delivery via prodrugs”, Advanced Drug Delivery Reviews 19:131-148 (1996).
Hauptmann et al, “Reduction of a benzamidoxime derivative to the corresponding benzamidine in vivo and in vitro”, Pharmazie 43:559 (1988).
Tatsumi and Ishigai, “Oxime-Metabolizing Activity of Liver Aldehyde Oxidase”, Archives of Biochemistry and Biophysics 253(2):413-418 (1987).
G. Claeson, “Synthetic peptides and peptidomimetics . . . ” Blood Coagulation & Fibrinolysis, vol. 5, pp. 411-436 (1994).
Chung, et al; Conformationally Constrained Amino Acids. Synthesis and Optical Resolution of 3-Substituted Proline Derivatives;J. Org. Chem. 55,pp. 270-275 (1990).
Marki, et al; “The Anticoagulant and Antithrombotic Properties of Hirudins”;Thrombosis and Haemostasis; F.K. Schattauer Veriagsgesellschaft mbH (Stuttgart) 64(3) pp. 344-348 (1990).
Stewart et al, “Solid Phase Peptide Synthesis,” Pierce Chemical Co., pp. 18-20 (w/appendix), 1969.
Bajusz, “Interaction of Trypsin-like Enzymes with Small Inhibitors,” Symposia Biologica Hungarica 25, pp. 277-298, (1984).
Jackson et al, “Pharmacological Assessment of the Antithrombotic Activity . . . ,” J. of Pharm. Exp. Ther., vol. 261, pp. 546-552 (1992).
Knabb et al, “IN Vivo Characterization of New Synthetic Thrombin Inhibitor,” Thrombosis and Haemostasis, vol. 67, No. 1, pp. 56-59 (1992).
Bajusz et al, “Inhibition of Thrombin with H- and Boc-D-Phe-Pro-Agm,” Chem. Abs. 99: 205609w (1993).
Klement et al, “The Effect of Thrombin Inhibitors on Tissue Plasminogen . . . ,” Thrombosis and Haemostasis, vol. 68, No. 1, pp. 64-68 (1992).
Märki et al, “The Anticoagulant and Antithrombotic Properties of Hirudins,” Thormsos and Haemostasis, vol. 64, No. 3, pp. 344-348 (1990).
Broersma et al, “The Effect of Thrombin Induction Inhibition in a Rat Arterial Thrombosis Model,” Thrombosis Research, vol. 64, pp. 405-412 (1991).
Persson et al, Thorax, vol. 47, pp. 993-1000 (1992).
Salomonson et al, Am. Rev. Resp. Dis., vol. 146, pp. 1535-1542 (1992).
Markwardt et al, Biochem. Pharm., vol. 23, pp. 2247-2256 (1974).
Malek et al, “Palladium-catalyzed synthesis of Cinnamylamides,” J. Org. Chem., vol. 47, No. 27, pp. 5395-5397 (1982).
Malek et al, Chem. Abs. 98: 16353 (1983).
Glusa et al, “The influence of benzamidine derivatives on human platelet function,” Thrombosis et Diathesis Haemorrhagica, vol. 31, pp. 172-178 (1974).
Anderson and Lok, J. Organic Chem., vol. 37, p. 3953 (1972).
Fareed et al, Ann. N.Y. Acad. Sci., vol. 370, pp. 765-784 (1981).
Geratz, J.D., “Inhibition of thrombin, plasmin and plasminogen compounds,” Thrombosis et Diathesis Halmorrhagica, vol. 23, No. 3, pp. 486-499 (1970).
Clement, B., et al; “N-Hydroxylation of the Antiprotozoal Drug Pentamidine Catalyzed by Rabbit Liver Cytochrome P-450 2C3 or Human Liver Microsomes, Microsomal Retroreduction, and Further Oxidative Transformation of the Formed Amidoximes”;Drug Metabolism and Disposition; vol. 22, No. 3, pp. 486-497 (1994).
Chung et al, J. Organic Chem., vol. 1, pp. 270-275 (1990).
Clement, B., et al; “Reduction of Amidoxime Derivatives to Pentamidine in vivo”;Arch. Pharm. (Welnheim); vol. 325; pp. 61-62 (1992).
G. Claeson, “Synthetic peptides and peptidomimetics . . . ” Blood Coagulation & Fibrinolysis, vol. 5, pp. 411-436, 1994.
B. Blomback et al, “Synthetic peptides with anticoagulant and Vasodilating . . . ” Scand. J. Clin. Lab. Invest. Suppl 107, pp. 59-64 (1969).

Affiliated with

Also associated with

Rating

Prodrugs of thrombin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs of thrombin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of thrombin inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3917651